1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited

TLX.AX
Telix Pharmaceuticals LimitedAU flagAustralian Securities Exchange
12.20
AUD
-0.43
- -
4.13BMarket Cap
Telix Pharmaceuticals Limited
TLX.AX
(Australian Securities Exchange)

Recent

price

12.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

1999
2000
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
0.01
0.01
0.01
0.35
1.04
1.56
2.52
- -
Revenue per Share
-0.01
-0.01
- -
-0.05
-0.05
-0.08
-0.17
-0.21
-0.34
0.01
0.1
-0.02
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
-0.04
-0.02
-0.07
-0.14
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.31
- -
0.38
0.15
0.29
0.14
0.16
0.32
-0.59
-0.46
-0.48
- -
Book Value per Share
- -
0.13
- -
0.29
0.05
0.08
0.06
-0.19
-0.01
0.09
0.29
-0.56
- -
Tangible Book Value per Share
39
39
- -
128
202
233
257
282
311
319
331
319
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
2
4
4
109
333
517
804
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
-20,113.07
-1,649.99
-1,383.61
-2,782.62
-46.34
10.5
10.76
2.25
- -
Operating Margin (%)
- -
- -
- -
- -
- -
3
5
5
4
7
- -
- -
- -
Depreciation Expense
- -
- -
- -
-6
-10
-20
-45
-58
-104
4
34
-7
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
11.16
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
-7,087.06
-799.63
-1,247.47
-1,643.73
-95.56
1.26
6.52
-0.89
- -
Profit Margin (%)
- -
3
53
48
30
51
78
7
115
47
365
99
47
Working Capital
- -
- -
- -
- -
- -
1
1
1
7
11
347
448
11
LT Debt
- -
5
40
38
37
49
61
2
54
103
353
415
103
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
11.2
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
340.45
- -
- -
Return on Capital (%)
- -
-8.41
- -
-14.33
-24.44
-39.65
-86.86
-144.87
-145.32
3.71
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'23
Sep'23
Dec'23
ST Debt
1
- -
1
LT Borrowings
12
- -
6
LT Finance Leases
- -
- -
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
324
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jun'23
Sep'23
Dec'23
Total Current Assets
219
- -
159
Cash, Cash Equivalents & STI
87
- -
84
Accounts Receivable, Net
61
- -
44
Inventories
13
- -
13
Total Current Liabilities
94
- -
111
Payables & Accruals
39
- -
67
ST Debt
1
- -
1
Deferred Revenue
- -
- -
8

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
440.29%
726.4%
17.69%
Free Cash Flow
- -
302.34%
97.33%
Net Income, GAAP
- -
116.73%
-121.15%
Sales/Revenue/Turnover
- -
656.52%
55.61%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
333
2024
- -
- -
- -
- -
517
2025
- -
- -
- -
- -
804

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.01
2024
- -
- -
- -
- -
0.1
2025
- -
- -
- -
- -
-0.02

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Gemini Therapeutics, Inc. (GMTX)
Asymchem Laboratories (Tianjin) Co., Ltd. (6821.HK)
Aura Biosciences, Inc. (AURA)
Doseology Sciences Inc. (MOOD.CN)
Arcellx, Inc. (ACLX)
Telix Pharmaceuticals Limited (TLPPF)
Business
Telix Pharmaceuticals Limited (ASX: TLX), a commercial-stage biopharmaceutical company founded in 2015 and headquartered in Melbourne, Australia, develops and commercializes diagnostic and therapeutic radiopharmaceuticals, or theranostics, focused on precision oncology for urologic (prostate, kidney, bladder), neuro-oncologic (glioma), musculoskeletal (sarcoma), and hematologic cancers. The company operates through Therapeutics, Precision Medicine, Medtech, and Manufacturing Solutions segments, offering products including Illuccix (kit for the preparation of 68Ga-PSMA-11 injection) for PSMA-PET/CT imaging in prostate cancer staging, recurrence detection, and therapy selection; Gozellix (TLX007-CDx), Pixclara (TLX101-CDx), and Zircaix (TLX250-CDx) diagnostic imaging agents for prostate, glioblastoma, and kidney cancers pending U.S. FDA approval in 2025; SENSEI miniature gamma probe for surgical guidance; dosimetry software; AI diagnostic platforms; and an extensive pipeline of late-stage therapeutics such as TLX591 (177Lu-rosopatamab tetraxetan) for castration-resistant prostate cancer in Phase III trials with interim data expected in H1 2025, TLX250 (177Lu-girentuximab) for clear cell renal cell carcinoma, TLX101 (131I-IPA) for glioblastoma, and 90Y-besilesomab for bone marrow conditioning, alongside early-stage alpha-emitters targeting PSMA, CAIX, FAP, LAT, and PDGFR-alpha, plus 153Sm-DOTMP for bone metastases palliation. Telix maintains commercial operations in the United States, Europe (Belgium, Switzerland), Japan, Australia, Canada, and the United Kingdom, with global manufacturing facilities including a major radiopharmaceutical production site opened in Belgium in 2023. Recent developments include the November 2024 announcement to expand its theranostic pipeline with FAP-targeting candidates initially for bladder cancer to complement its urology franchise; the acquisition of IsoTherapeutics in 2024 to bolster U.S. R&D and manufacturing infrastructure; planned pivotal trials in 2025 for Zircaix in renal carcinoma and Pixclara in glioblastoma; and a record presence at EANM 2025 showcasing CAIX and FAP theranostics.

Company News

APIChat

  • prnewswire.com

    Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds

  • prnewswire.com

    Telix Refinances Convertible Bonds

  • globenewswire.com

    Telix choisit le Cyclone® KIUBE d’IBA pour étendre ses capacités de production aux États‑Unis

  • globenewswire.com

    Investor Education Webinar

  • globenewswire.com

    Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded